Scholar Rock LLC's first disclosed deal provides a glimpse into how the company thinks it can exploit new structural biology insights about well-trodden growth factor targets to develop new therapies.

The biotech has partnered with Johnson & Johnson's J&J Innovation and Janssen Biotech Inc. units to discover and develop biologics that can selectively modulate TGFB1 activity in local microenvironments without disrupting the growth factor's physiological activities elsewhere.